Author

Ozlem Sener Sahin

Medical University of South Carolina

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2

Frequent Co-Authors

Bürge UlukaniD· 2 shared Özge SaatciiD· 2 shared Yasser RiazalhosseiniiD· 2 shared Ariel MadrigaliD· 1 shared Aynur IşıkiD· 1 shared Ayşegül ÜneriD· 1 shared Aytekin AkyoliD· 1 shared Besim ÖğretmeniD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Bürge UlukanORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintJul 27, 2026

Lysyl oxidase drives ccRCC progression by coordinating HIF-2α transcription program with tumor microenvironment

Bürge Ulukan, Özge Saatci, Ariel Madrigal…·Ozgur Sahin

This study identifies LOX as a driver of ccRCC progression by sustaining HIF-2α transcription and modulating the tumor microenvironment.

DOI 10.64898/2026.07.24.739825

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyCell Death and DiseasePeer-reviewedJun 15, 2024

Targeting LINC00152 activates cAMP/Ca2+/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer

Özge Saatci, Rashedul Alam, Kim‐Tuyen Huynh‐Dam…·Özgür Şahin

This study identifies LINC00152 as a driver of tamoxifen resistance in ER+ breast cancer by inhibiting ferroptosis, and shows that targeting LINC00152 restores sensitivity to tamoxifen.

42 citationstop 3%

humanbulk RNA-seq

𝕏 PostBluesky